Currently out of the existing stock ratings of Chris Shibutani, 77 are a BUY (55.4%), 58 are a HOLD (41.73%), 4 are a SELL (2.88%).

Chris Shibutani

Work Performance Price Targets & Ratings Chart

Analyst Chris Shibutani, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 56.5% that have a potential upside of 17.89% achieved within 130 days.

Chris Shibutani’s has documented 276 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALKS, Alkermes Plc at 14-Feb-2025.

Wall Street Analyst Chris Shibutani

Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $117 was fulfilled within 1 day with a profit of $21.2 (22.13%) receiving and performance score of 221.29.

Average potential price target upside

of $33.66 (8.66%) on LLY (ELI LILLY AND COMPANY).
of $22.82 (32.84%) on RXDX (PROMETHEUS BIOSCIENCES).
of $20.42 (12.85%) on ABBV (ABBVIE).

ALKS Alkermes Plc BNTX BioNTech SE JNJ Johnson & Johnson MCRB Seres Therapeutics NBIX Neurocrine Biosciences NKTR Nektar Therapeutics PBYI Puma Biotechnology RVMD Revolution Medicines TNGX Tango Therapeutics UTHR United Therapeutics ABBV AbbVie BMY Bristol-Myers Squibb Company LLY Eli Lilly and Company PFE Pfizer AMLX Amylyx Pharmaceuticals EXAI Exscientia Ltd ADR TRDA Entrada Therapeutics EQRX EQRx RPRX Royalty Pharma Plc KYMR Kymera Therapeutics INVA Innoviva RXDX Prometheus Biosciences ERAS Erasca MDCO The Medicines Company RPTX Repare Therapeutics RVNC Revance The SDGR Schrodinger SNDX Syndax Pharmaceuticals OGN Organon ARQT Arcutis Biotherapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Chris Shibutani (GOLDMAN SACHS)